70 Talks Being Presented for the First Time or Featuring New DataCYT101, a High-Affinity IL-15Rbg Agonist, Induces Safe and Potent Anti-Tumor Immune Activities in Patients with Solid Tumors and Supports Further Clinical InvestigationsIrena Adkins, PhD, Science Lead, Pharmacology, SOTIO asPredicting Antibody Developability through Experimental and in silico ApproachesMarc Bailly, PhD, Principal Scientist, Merck Research LabsEfficient Production of Recombinant Secretory IgA against Clostridium Difficile Toxins in CHO-K1 CellsAnton Bauer, PhD, MBA, Medical University of ViennaPD-1 Antibodies as Precision Medicine Informed Mono- and Combination Therapies Are Transforming Cancer CareRoy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp and DohmeAntibody-Targeted Lipid-Nanoparticle Mediated Inhibition of the GPCR RXFP1 Signaling Pathway as a Therapeutic Approach for Ovarian CancerItai Benhar, PhD, Professor, Biomedicine & Cancer Research, Tel Aviv UniversityApplication of Molecular Dynamics Simulations for Developability Assessment and Formulation Development of BiologicsCarolin Berner, Chair of Pharmaceutical Technology & Biopharmaceutics, Pharmaceutics, University of Munich
iMAM: A High-Resolution LC-MS Intact Mass Analysis Multi-Attribute Method WorkflowJonathan Bones, PhD, Principal Investigator, Characterisation and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT)Targeting of Tumor-Specific Peptide Antigens with Bispecific T Cell-Engaging Receptor (TCER) MoleculesSebastian Bunk, PhD, Senior Director, ImmaticsAccelerated Predictive Stability for Biologicals and VaccinesDidier Clenet, Senior Scientist, Formulation & Stability & Bioprocess R&D, Sanofi Pasteur
Using Computational Structural Modelling to Identify the Precise Epitopes of Coronavirus-Binding AntibodiesCharlotte M. Deane, PhD, Professor of Structural Bioinformatics, Statistics, University of OxfordOptimizing the High-Yield Production of SARS-CoV-2 Proteins for Large-Scale Deployment of Serology AssaysDominic Esposito, PhD, Director, Protein Sciences, Frederick National LaboratoryExpression of a Pathogenic Virulence Factor Enhances the Efficacy of CAR-T Cell Therapy Against Solid TumorsMagnus Essand, PhD, Co-Founder, Elicera Therapeutics; Prof, Immunology, Genetics and Pathology, Uppsala UniversityAntibody CDR Design Using High-Capacity Machine LearningStefan Ewert, PhD, Senior Investigator, Biologics Center, Novartis Institutes for Biomedical ResearchBeehive Hexagonal Structures for Agonism and Antagonism – The TNFR2 ParadigmDenise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General HospitalPreclinical Development of NI-1801, a MSLN/CD47 Bispecific AntibodyNicolas Fischer, PhD, CEO, Light Chain Bioscience
A First in Class Anti-TNFR2 Ab (BI-1808) for Single Agent and Anti-PD-1 Combination Immunotherapy of CancerBjörn L. Frendeus, PhD, CSO, BioInvent International ABA Compact Vocabulary of Paratope-Epitope Interactions Enables Predictability of Antibody-Antigen BindingVictor Greiff, PhD, Associate Professor, Immunology, University of Oslo, NorwayTargeting Perivascular Macrophage Tumor Vasculature Interactions to Restore an Immune-Competent Tumor MicroenvironmentRené M.A., Hoet, PhD, CSO, Montis Biosciences BVA Novel Tumor Selective Anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor MicroenvironmentYuji Hori, PhD, Research Scientist, Discovery Biological, Chugai Pharmaceutical Co. Ltd.Development of Multispecific Assemblies of Nanofitins with Anti-Tumor ActivitiesPerrine Jacquot, Junior Project Manager, Affilogic
mRNA-Based COVID-19 Vaccines: Structure, Formulation and StabilityWim Jiskoot, PhD, Professor, Drug Delivery Technology, Leiden UniversityDevelopment of a High-Throughput cIEF Method for Quantification of Full and Empty Viral Particles for Cell and Gene TherapiesJenifer Kaplan, PhD, Principal Scientist I, Novartis Institutes for Biomedical Research
Finding the Needle in the Haystack – A New Method for Selecting High-Producing Stable CellsDennis Karthaus, MSc, Director, Protein Products & Assays, IBA Lifesciences
Engineered Glutathione S-Transferase Tag Suitable for High-Yield Soluble Expression at Low TemperatureTakanori Kigawa, PhD, Team Leader, Laboratory for Cellular Structural Biology, RIKEN Center for Biosystems Dynamics ResearchEngineering Antibodies for Next-Generation Cancer ImmunotherapyChristian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pREDSelecting the Right Antibody Using Complex Phage Selections and NGSPeter Kristensen, PhD, Associate Professor & Head of Biotechnology, Chemistry & Bioscience, Aalborg UniversityA Pivotal Role for Concurrent Chemotherapy and γδ T Cell Therapy (Drug Resistant Immunotherapy - DRI) in the Post Induction Primary Disease Setting for Reducing the Immunosuppressive Properties of the Tumor MicroenvironmentLawrence Lamb, Jr., PhD, Executive Vice President & CSO, Incysus Therapeutics, Inc.CHO Cell Line Development and Engineering via Site-Specific Integration: Challenges and OpportunitiesJae Seong Lee, PhD, Assistant Professor, Applied Chemistry & Biological Engineering, Ajou UniversityExtending the Half-Life of IgA as Therapeutic Antibody through AlbuminJeanette H.W. Leusen, PhD, Associate Professor, Translational Immunology, Utrecht UniversityDevelopment of an Anion Exchange Chromatography Assay for Determining Empty and Full AAV Capsid Content in AAV6.2Thomas Linke, Senior Scientist, Process Development, AstraZenecaICT01: A First-in-Class Clinical Stage Anti-BTN3A Antibody with the Capacity to Harness the Vg9/Vd2 T Cells in CancerLoui Madakamutil, PhD, CSO, ImCheck TherapeuticsAntibody Discovery, Affinity Maturation and Developability Screening from Large Mammalian Display LibrariesJohn D. McCafferty, PhD, CEO & Founder, IONTAS and CEO and Founder, Maxion TherapeuticsNKT Cells as a Platform for Redirected Cancer ImmunotherapyLeonid S. Metelitsa, MD, PhD, Professor, Pediatrics & Oncology, Baylor College of MedicineDeep Neural Networks in Protein Engineering – From Predicting Stabilizing Sequences to Refining 3D StructuresAbhishek Mukhopadhyay, PhD, Principal Scientist and Group Lead, Molecular Simulations, Zymeworks, Inc.Next-Generation Antibody-Cytokine Fusions for Cancer TherapyDario Neri, PhD, Full Professor, Chemistry & Applied Biosciences, ETH ZurichTo Sub 10 pM Affinity and Beyond! Discovery of a Next-Generation Highly Potent Long-Acting Anti IL-5 AntibodyMartin A. Orecchia, PhD, Team Leader, Antibody Discovery, GlaxoSmithKlinePreclinical Pharmacokinetics, Pharmacodynamics and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple MyelomaAyse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.Shifting from T to NK ImmunotherapyAviad Pato, PhD, Head Research, Natural Killer Cells, Gamida Cell Ltd.
Targeting Glycan-Mediated Immune Regulation in Cancer and Inflammatory DiseasesLi Peng, PhD, Senior Vice President, Research & Early Product Development, Palleon PharmaceuticalsBoltbody Immune Stimulating Antibody Conjugates (ISACs): From Preclinical to Clinical ResearchEdith A. Perez, MD, CMO, Bolt Biotherapeutics, Inc.Analytical Ultracentrifugation: An Auxiliary Tool for Vector CharacterizationRobert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, TakedaThe SHREAD Platform: SHielded, REtargeted ADenovirus for Paracrine Delivery of TherapeuticsAndreas G. Plueckthun, PhD, Professor & Head, Biochemistry, University of ZurichCharacterization of Adeno-Associated Virus-Based Gene Therapy Products by Mass SpectrometryYi Pu, PhD, Scientist II, Analytical Development, BiogenAdvancing Mass Spectrometry Technology in cGMP EnvironmentsDa Ren, PhD, Scientific Director, Process Development, Amgen Inc.Downstream Process of Adeno-Associated Viruses (AAV) – Purification, Characterisation and FormulationRuth Rieser, PhD Student, Pharmacy, Ludwig Maximilians UniversityEnhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein through Structure-Guided DesignTimothy Riley, PhD, Scientist, Amgen Inc.
Next-Generation CAR T Cells in the ClinicClaire Roddie, PhD, Researcher, CAR T Cell Program, University College LondonCharacterization and Monitoring of Cell Therapy Attributes Using Mass SpectrometryRichard Rogers, PhD, Associate Director, Bristol-Myers SquibbA Valuable Alternative to Mammalian Systems: Baculovirus-Free Antigen and Antibody Expression in Insect CellsMaren Schubert, Technical University of Braunschweig
Is There Safe Storage Temperature for Frozen and Freeze-Dried Biologicals?Evgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, Abbvie, Inc.Multimeric IgM Antibodies Targeting DR5 are Potent and Rapid Inducers of Tumor Cell Apoptosis in vitro and in vivoAngus M. Sinclair, PhD, Vice President, Immuno-oncology Research, IGM BiosciencesTargeting the Immune Inhibitory Receptor LILRB4 to Treat Acute Myeloid LeukemiaAn Song, PhD, CSO, Immune Onc Therapeutics Inc.Third-Generation Methods of Antibody Discovery and Optimisation: In silico Rational DesignPietro Sormanni, PhD, Royal Society University Research Fellow, Yusuf Hamied Department of Chemistry, University of Cambridge
Integrating Synthetic Biology and Computer-Aided Design to Advance Mammalian BioproductionRaja Srinivas, PhD, Co-Founder, Asimov, Inc.Ultra-Dilute Solution Measurements of Antibody Self-AssociationCharles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi GroupCombinatorial Targeting of Multiple Myeloma by Complementing T Cell Engaging Antibody FragmentsGernot Stuhler, MD, Senior Physician & Group Leader, Hematology & Oncology & Medical Clinic II, University Hospital WuerzburgNot Grams and Not Even Milligrams Per Liter: Strategies for Homeopathic Protein ProductionSabine Suppmann, PhD, Head, Recombinant Protein Production, Max Planck Institute of Biochemistry
Rational Screening of Compatible Monoclonal Antibodies for Development as Fixed-Dose CombinationsHristo Svilenov, PhD, Researcher, Technical University Munich, Germany
Maximizing the Therapeutic Potential of Allogeneic Natural Killer CellsJoanne B.L. Tan, PhD, Director, Translational Biology, Nkarta Inc.NMR Tools for the Assessment of Antibody-Drug Candidates Aggregation StatePablo Trigo Mourino, PhD, Senior Scientist, Analytical Research & Development, MSDFAP-CD40, a Novel Tumor-Stroma Targeted CD40 Agonist, Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Anti-Tumor ImmunityChristine Trumpfheller, PhD, Senior Scientist, Roche Innovation Center ZurichAugmented Antibody-Based Anticancer Therapeutics Boost Neutrophil CytotoxicityMarjolein van Egmond, PhD, Professor, Oncology and Inflammation, Amsterdam UMC, The NetherlandsMultifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor ImmunityÉric Vivier, DVM, PhD, CSO, Innate PharmaTargeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor ImmunityHong I. Wan, PhD, President, CEO and Co-Founder, Tallac Therapeutics, Inc.Structures of Mouse and Human GITR-GITRL Complexes Reveal Unique TNFSF InteractionsFeng Wang, PhD, Associate Director, Recombinant Proteins, Bristol-Myers SquibbThe Temporal Dynamics of the Humoral Immune Response Following COVID-19 Recovery and Immunisation with mRNA VaccineYariv Wine, PhD, Assistant Professor, The Shmunis School of Biomedicine and Cancer Research, Tel Aviv UniversityNative SEC-MS for Characterizing Therapeutic Monoclonal Antibodies: A Glimpse in the Formation Mechanism of Antibody AggregatesJing Xu, PhD, Scientist I, Analytical Chemistry, BiogenEngineering Cis-Targeted Immunomodulators to Enhance Their Selectivity and Effectiveness as TherapeuticsYik Andy Yeung, PhD, CTO, Asher BiotherapeuticsTargeting B Cell Malignancies with Multi-Specific Cytotoxic CD4+ T CellsBaochun Zhang, PhD, Assistant Professor, Medical Oncology, Dana Farber Cancer InstituteEfficient NK Cell Redirection byTargeting NKp30Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA
* As of 28 July. Please see individual agenda pages for most current speaker information.